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Treatment with anti-TGF-b antibody ameliorates chronic pro-
gressive nephritis by inhibiting Smad/TGF-b signaling.
Background. Although short-term treatment with anti-
transforming growth factor-b (TGF-b) antibody (aT) has been
shown to prevent early glomerular lesions, its long-term effects
and molecular mechanisms, including intracellular signaling, re-
main poorly understood. We examined whether aT treatment
induces prevention of renal insufficiency and fibrosis, and af-
fects the TGF-b/Smad signaling pathway in rats with chronic
progressive anti-thymocyte serum (ATS) nephritis induced by
repeated ATS injections on days 0 and 7.
Methods. Nephritic and non-nephritic rats were treated with
either aT or control immunoglobulin (Ig)G twice weekly for
4 weeks from days 7 to 35 (each group, N = 21). Renal lesions
and cortical expression of TGF-b1, TGF-b2, TGF-b3, type II
TGF-b receptor (TbRII), Smads, type I collagen, and plas-
minogen activator inhibitor-1 were examined by immunohisto-
chemistry, Western blot, and/or real-time reverse transcription
polymerase chain reaction (RT-PCR). The binding of Smad3 in
renal cortical cell nuclei to the Smad-binding element (SBE)
was investigated by the electrophoretic mobility shift assay.
Results. Nephritic rats developed heavy proteinuria, renal
insufficiency, and increased extracellular matrix deposition re-
sulting in renal fibrosis. Cortical expression levels of TGF-b1,
TGF-b2, TbRII, and Smad2, but not TGF-b3, Smad3, and
Smad4 were increased. Expression and preferential localiza-
tion of phosphorylated Smad2/3 in the glomerular and tubular
cell nuclei, and Smad3-SBE complex-forming activity were also
increased. Four-week aT treatment resulted in marked amelio-
ration of chronic progressive ATS nephritis at 8 weeks.
Conclusion. In chronic progressive ATS nephritis, the TGF-
b/Smad signaling was up-regulated. TGF-b blockade by aT sup-
pressed the progression of renal scarring, at least in part, via
inhibition of activated TGF-b/Smad signaling.
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Several lines of evidence indicate that overexpression
of transforming growth factor-b (TGF-b) in the kidney
underlies the development of renal fibrosis resulting from
accumulation of extracellular matrix (ECM) in chronic
progressive nephropathies [1]. Because the progression
of renal fibrosis is the final common feature at the end-
stage of various renal diseases and its level correlates with
renal prognosis, TGF-b is thought to be a key molecule
involved in the progression of chronic kidney diseases
that lead to renal death [2].
TGF-b exerts its biologic effects through binding
to specific cell surface receptor proteins, composed of
two transmembrane serine/threonine kinases, designated
type I (TbRI) and type II (TbRII) TGF-b receptors
(TbR). Smad proteins are important signaling transduc-
ers from those receptors to the target genes in the nu-
cleus. Three families of Smads have been identified: (1)
receptor-regulated Smad2 and Smad3 (R-Smads); (2)
common partner Smad4 (Co-Smad); and (3) inhibitory
Smad6 and Smad7 (I-Smads). The activated TGF-b re-
ceptors induce phosphorylation of Smad2 and Smad3,
which form hetero-oligomeric complexes with Smad4. In
response to TbR activation, such complexes translocate
to the nucleus, where they regulate transcriptional re-
sponses together with additional DNA binding cofactors
[3].
Recently, several monoclonal antibodies to specific cy-
tokines, such as interleukin-6 and tumor necrosis factor-a,
have been clinically adopted for the treatment of vari-
ous diseases, including rheumatoid arthritis and inflam-
matory bowel diseases. Similarly, inhibition of TGF-b has
been proposed as a therapeutic strategy for prevention of
renal fibrosis. To date, it has been reported that inhibition
of TGF-b by neutralizing anti-TGF-b antibody (aT) [4–
9], anti-sense oligonucleotide [10] and decorin [11] can
suppress intrarenal ECM accumulation in rats with acute
reversible mesangial proliferative glomerulonephritis in-
duced by a single injection of anti-Thy-1.1 antibody [4,
10, 11], streptozotocin-induced diabetic mice [5], db/db
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diabetic mice [6], rats with unilateral ureteral obstruc-
tion [7], and rats [8] and mice [9] with cyclosporin A
nephropathy. However, most of these studies [4, 7, 8, 10–
12] examined the short-term effects of TGF-b inhibition.
Although two other studies investigated the long-term
effects of aT in db/db diabetic mice [6] and mice with
cyclosporin A nephropathy [9], the renal lesions in these
models are dissimilar to those of human chronic progres-
sive glomerulonephritis associated with tubulointerstitial
lesions resulting in end-stage renal failure because no
evident tubulointerstitial lesions developed in the for-
mer model, and the latter lacked glomerular damage
and proteinuria. Therefore, at present, it remains unclear
whether inhibition of TGF-b could exert long-term ben-
eficial effects in chronic progressive glomerulonephritis.
Furthermore, the molecular mechanisms involved in the
profibrotic roles of TGF-b signaling system have been
poorly documented.
To answer these questions, we adopted an experimen-
tal model of chronic progressive glomerulonephritis that
was induced by repeated anti-thymocyte serum (ATS) in-
jections. In this model, the animal develops irreversible
glomerulosclerosis and tubulointerstitial fibrosis after the
second ATS injection, associated with a gradual decline
of renal function, and we also demonstrated previously a
progressive increase in expression of TGF-b1 and types I,
II, and III TGF-b receptors in the glomerular and tubu-
lointerstitial lesions [13, 14]. Using this unique model,
we studied the long-term effects of treatment with neu-
tralizing aT in preventing proteinuria, renal insufficiency,
renal fibrosis, and TGF-b/TbR/Smad signaling pathway.
Treatment with aT significantly prevented proteinuria,
renal insufficiency, and fibrosis. In addition, our findings
present a complete picture of how the ligand, its recep-
tor, and signaling components of the renal TGF-b system
interact to promote the progression of glomerulonephri-
tis with tubulointerstitial fibrotic lesions. To our knowl-
edge, this is the first study that provides strong support
for the premise that periodic inhibition of the biologic
actions of TGF-b could prevent renal scarring, at least in
part via down-regulation of pathologic TGF-b signaling
in chronic progressive glomerulonephritis.
METHODS
Experimental animals and design
ATS was raised in non-pregnant adult female England
Suffolk sheep as described previously [14]. All animals
were treated according to the protocols approved by the
Hamamatsu University School of Medicine Animal Care
Committees at the Center Animal Care facility.
Male Wistar rats, weighing 150 g at the start of the
experiment, were purchased from SLC (Hamamatsu,
Shizuoka, Japan) and allowed free access to food and wa-
ter. Eighty-four rats were divided into four groups includ-
ing rats with chronic progressive ATS nephritis–treated
with monoclonal neutralizing aT (N = 21), chronic pro-
gressive ATS nephritis rats treated with isotype-matched
irrelevant immunoglobulin (Ig)G (N = 21), non-nephritic
rats treated with aT (N = 21), and non-nephritic rats
treated with irrelevant IgG (N = 21). Chronic progres-
sive ATS nephritis was induced by repeated intravenous
injections of 1.5 mL of ATS at days 0 and 7 [13, 14].
Rats that received intravenous injections of 1.5 mL of
0.15 mol/L phosphate-buffered saline (PBS, pH 7.4), at
days 0 and 7, were adopted as non-nephritic animals. The
murine IgG1 j monoclonal aT neutralizes all three iso-
forms (-b1, -b2, and -b3) of TGF-b and has a circulat-
ing half-life of 15.2 hours in rat (1D11; ATCC HB-9849,
Manassas, VA, USA). The efficacy and safety of this anti-
body has been reported in some in vivo studies conducted
by other investigators [7, 9]. Therapeutic intervention us-
ing intraperitoneal injection of 2 mg of aT was started
6 hours after the second injection of ATS or PBS at day 7.
Administration of aT was performed twice weekly for
4 weeks ending at day 35. As a control treatment, isotype-
matched irrelevant IgG was administered instead of aT.
Seven rats each in the four groups were sacrificed at day
0, and 4 and 8 weeks after the beginning of this protocol.
The kidneys were perfused with ice-cold PBS and the re-
nal cortical tissues were removed and reserved for the
examinations described below.
Urinary protein excretion and blood urea
nitrogen levels
Rats were housed in metabolic cages for a 24-hour
urine collection under 12-hour light/12-hour dark cycle
at days 0 and 3, and 1, 2, 4, 6, and 8 weeks after the be-
ginning of this protocol. Urinary protein concentration
was measured by a pyrogallol red method. The levels of
blood urea nitrogen were measured as a marker of renal
function at the end of the study period using the standard
method.
Measurement of hydroxyproline (OH-proline)
The renal cortical tissues were fixed in acetone and
frozen at −20◦C until assayed. The OH-proline concen-
tration (lg/mL) of the renal cortex was determined after
dehydration and hydrolysis by hydrochloric acid, using
the method of Woessner [15]. The concentration was cor-
rected by tissue dry weight (lg/mg tissue).
Histopathologic and immunohistochemical analysis
Kidney tissues were fixed in 4% paraformaldehyde
in PBS and embedded in paraffin. Three-lm thick tis-
sue sections were stained with periodic acid-Schiff for
histopathologic analysis. To assess the acute and chronic
histopathologic changes, we employed the methods of
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Austin et al [16] with minor modifications. In brief, a
semiquantitative grade of severity (0, 1, 2, or 3+, indi-
cating that the feature was absent, mild, moderate, or
severe, respectively) was assigned to each of the follow-
ing morphologic attributes: (1) glomerular cell prolifera-
tion; (2) leukocyte exudation; (3) the presence of cellular
crescents; (4) interstitial mononuclear-cell infiltration; (5)
glomerular sclerosis; (6) the presence of fibrous crescents;
(7) tubular atrophy; and (8) interstitial fibrosis. The pres-
ence of cellular crescents was weighed by a factor of two
because such lesion has been considered to be dispro-
portionately ominous. Composite scores were calculated
by summing individual scores for attributes 1 through 4
to arrive at an activity index and by summing individual
scores for attributes 5 through 8 to arrive at a chronicity
index.
Immunoreactivity for phosphorylated Smad2/3
proteins was determined using a standard biotin-
streptavidin-peroxidase method as described previously
[14]. The primary antibody was rabbit anti-human
phosphorylated Smad2/3 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The secondary antibody was
affinity-purified biotinylated donkey anti-rabbit IgG
(Cortex Biochem, San Leandro, CA, USA). Endogenous
peroxidase activity was blocked by incubation in 3%
hydrogen peroxide for 20 minutes. Reaction products
were visualized using a color solution that consisted
of 20 mg 3,3′-diaminobenzidine (DAB), 40 mg sodium
azide, and 35 lL of 30% hydrogen peroxide in 100 mL of
0.05 mol/L Tris-HCl buffer, pH 7.6. Sections incubated
with nonimmune rabbit sera instead of the primary
antibodies were used as negative controls. Nuclei were
counterstained lightly with hematoxylin. All sections
were stained under identical conditions together with
control incubation.
Double immunostaining for TbRII and phosphory-
lated Smad2/3 was performed using the methods of Lan
et al [17]. After immunostaining the sections with phos-
phorylated Smad2/3 using DAB, sections were heated in a
microwave oven for 10 minutes in 0.01 mol/L sodium cit-
rate, pH 6.0, set at 800 W, then incubated with anti-TbRII
antibody (Santa Cruz Biotechnology), washed with PBS,
and incubated with biotinylated donkey anti-rabbit IgG
(Cortex Biochem). Then, Vectastain ABC-AP reagent
(Vector Laboratories, Burlingame, CA, USA) was added
and the Vector Red Alkaline Phosphatase Substrate Kit
I (Vector Laboratories) was used as chromogen. Nuclei
were counterstained lightly with hematoxylin.
For immunofluorescence analysis, 3-lm thick frozen
sections were cut with a cryostat, air dried, and fixed
in acetone for 15 minutes. The primary antibody was
rabbit anti-rat type I collagen (Chemicon International,
Temecula, CA, USA). The secondary antibody was fluo-
rescein isothiocyanate-conjugated affinity-purified swine
anti-rabbit IgG (Dako, Glostrup, Denmark). Renal lo-
calization of type I collagen was investigated with an im-
munofluorescence microscope (BX50, Olympus, Tokyo,
Japan).
Preparation of nuclear extracts
To examine the nuclear localization of phosphorylated
Smad2 and Smad3 by Western blot analysis and the bind-
ing of Smad3 in the renal cortical cell nuclei to the Smad-
binding element (SBE) using electrophoretic mobility
shift assay (EMSA), nuclear extracts from renal cor-
tex were prepared according to the method of Jeremiah
et al [18] with minor modifications. In brief, renal cor-
tical tissues were minced and disrupted in 10 volumes
(about 1 mL) of 10 mmol/L HEPES, pH 7.9, 10 mmol/L
potassium chloride, 0.1 mmol/L EDTA, 0.1 mmol/
L EGTA, 0.1 mmol/L DTT, 1 mmol/L phenylmethyl-
sulfonyl fluoride (PMSF), 1 lg/mL aprotinin, 1 lg/mL
leupeptin, 1 lg/mL pepstatin A, 0.1 mmol/L sodium or-
thovanadate, 1 mmol/L sodium fluoride, and 10 mmol/L
b-glycerophosphate by 6 strokes in glass Teflon ho-
mogenizers on ice. Detergent Nonidet P-40 was added
to a final concentration of 0.7% and the homogenates
were centrifuged at 7000g for 30 seconds. The pellets
were suspended in fresh homogenization buffer and re-
centrifuged at 7000g for 30 seconds. The resulting pel-
lets were re-suspended in 0.3 mL of 20 mmol/L HEPES,
pH 7.9, 400 mmol/L sodium chloride, 1 mmol/L EDTA,
1 mmol/L EGTA, 1 mmol/L DTT, 1 mmol/L PMSF, 1 lg/
mL aprotinin, 1 lg/mL leupeptin, 1 lg/mL pepstatin A,
0.1 mmol/L sodium orthovanadate, 1 mmol/L sodium
fluoride, and 10 mmol/L b-glycerophosphate. The re-
suspended pellets were then incubated on ice for 20 min-
utes with periodic pipetting and centrifuged at 10,000g for
30 minutes. The supernatants were removed and aliquots
were frozen at −70◦C.
Western blot analysis
Kidney cortical tissues were dissolved in Triton X-
100 lysis buffer [50 mmol/L Hepes (pH 7.5), 300 mmol/
L NaCl, 0.5% Triton X-100] at 4◦C containing 1 mmol/
L PMSF, 1 lg/mL aprotinin, 1 lg/mL leupeptin,
1 lg/mL pepstatin A, 0.1 mmol/L sodium orthovana-
date, 1 mmol/L sodium fluoride, and 10 mmol/L b-
glycerophosphate. Equal amounts of proteins (40 lg)
were loaded for sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) as described previ-
ously [14]. The primary antibodies were rabbit anti-
human TbRII, phosphorylated Smad2/3 and Smad4
(Santa Cruz Biotechnology), rabbit anti-human Smad2
(Zymed Laboratory, South San Francisco, CA, USA),
rabbit anti-human Smad3 (Upstate Biotechnology, Lake
Placid, NY, USA), rabbit anti-rat plasminogen activa-
tor inhibitor-1 (PAI-1) (American Diagnostica, Green-
wich, CT, USA), and mouse monoclonal anti-b-actin
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(Sigma, St. Louis, MO, USA). b-actin was used as an in-
ternal control. Quantification of the band intensity was
performed using National Institutes of Health image
software.
RNA isolation and quantitative analysis of mRNA
by real-time RT-PCR
Total RNA was extracted from renal cortical tissue
using ISOGEN (Nippon Gene, Inc., Tokyo, Japan) ac-
cording to the instructions provided by the manufacturer.
Reverse transcription (RT) of the RNA was performed
using the first-strand cDNA synthesis kit (Roche,
Mannheim, Germany) and 1 lg of total RNA. For real-
time PCR, the Light Cycler PCR and detection system
(Roche) were used for amplification and online quantifi-
cation. All PCR experiments were performed using the
QuantiTectTM SYBR Green PCR kit purchased from
Qiagen (Tokyo, Japan). The amplification program con-
sisted of 1 cycle at 95◦C with a 10-minute hold (hot start)
followed by 50 cycles at 95◦C with a 15-second hold, 58◦C
annealing temperature with a 5-second hold, and 72◦C
with a 20-second hold. Amplification was followed by a
melting curve analysis to verify the accuracy of the PCR
products. The PCR-primer sequences were as follows: rat
TGF-b1 (sense: 5′-ACCGCAACAACGCAATCTAT-3′
and antisense 5′-ACGCCAGGAATTGTTGCTAT-3′),
rat TGF-b2 (sense: 5′-TGGCTTCACCACAAAGAC
AG-3′ and antisense 5′-CCATCGATACCTGCGAAT
CT-3′), rat TGF-b3 (sense: 5′-CCAAGACCTGGAGCC
TCT-3′ and antisense 5′-CCTCAGCTGCACTTACAC
GA-3′), rat a2 type I collagen (COL1A2) (sense: 5′-
TGTTCGTGGTTCTCAGGGTAG-3′ and antisense 5′-
TTGTCGTAGCAGGGTTCTTTC-3′), rat PAI-1 (sense:
5′-CTTTATCCTGGGTC TCCCTG-3′ and antisense
5′-TGATGCCTCCCTGACATACA-3′), and rat glycera-
ldehyde-3-phosphate dehydrogenase (GAPDH) (sense:
5′-AGGACCA GGTTGTCTCCTGT-3′ and antisense
5′-TTACTCCTTGGAGGCCATGT-3′). As negative
controls, RNA of the samples that were not reverse
transcribed was run to assess the specificity of the reac-
tion. To verify the accuracy of PCR amplification, PCR
products were analyzed on an ethidium bromide–stained
2% agarose gel.
Data analysis was performed using Light Cycler soft-
ware version 3.3.9 provided by Roche. To quantify the
gene copy number of the target cDNA that was re-
verse transcribed from RNA in the samples, 1:10 serially-
diluted PCR products of the target cDNA, which had
been generated beforehand using the same primers as
described above and purified by QIAquick PCR Purifi-
cation Kit (Qiagen), were included in each run and the
standard curves were obtained. The ratios of TGF-
b1, TGF-b2, TGF-b3, COL1A2, and PAI-1 mRNA to
GAPDH mRNA were calculated in each sample.
Table 1. Body weight of nephritic and non-nephritic rats treated with
aT or irrelevant IgG
Body weight g
0 week 4 week 8 week
Non-nephritic rats
IgG 171.5 ± 2.5 259.8 ± 3.2 295.7 ± 4.5
aT 170.2 ± 1.9 255.6 ± 6.3 293.1 ± 5.1
Nephritic rats
IgG 174.6 ± 1.8 234.9 ± 4.9a 266.8 ± 3.1a
aT 168.5 ± 2.5 232.4 ± 4.2a 270.5 ± 2.3a
Values represent mean ± SEM for 7 rats in each group.
aP < 0.05 vs. non-nephritic rats at the corresponding time period.
Electrophoretic mobility shift assay (EMSA)
Double-strand oligonucleotides that contain three rep-
etitions of the AGCCAGAC Smad-binding element
(SBE) in PAI-1 promoter were purchased from Santa
Cruz Biotechnology, and this SBE has been shown to
bind specifically with Smad3/4 complex [19]. EMSA was
performed as described previously [20]. Binding interac-
tion of the nuclear proteins, which had been isolated from
the renal cortical tissues of nephritic and non-nephritic
rats treated with either aT or IgG to the SBE oligonu-
cleotides, was performed in a final volume of 13 lL
containing 2 lL of nuclear extracts containing 4 lg of
proteins, 3 lL of binding buffer (100 mmol/L HEPES,
1 mmol/L EDTA, 20 mmol/L MgCl2, 250 mmol/L KCl,
25 mmol/L DTT, and 50% glycerol), 1 ng of radiolabeled
probes resuspended in 1 lL, 2 lg of poly-dIdC in 2 lL, and
5 lL of antibodies (5 lg) where necessary. The mixtures
were incubated for 60 minutes at 30◦C and DNA protein
complexes were separated by electrophoresis on a 4%
polyacrylamide gel in 0.5× Tris/borate/EDTA (TBE).
Statistical analysis
All values are shown as mean ± SEM. Differences be-
tween groups were examined for statistical significance
using analysis of variance (ANOVA). When a significant
difference was present, statistical analysis was further per-
formed using the Scheffe F test between the two groups.
A P value less than 0.05 denoted the presence of a statis-
tically significant difference.
RESULTS
Body weight of rats treated with aT or irrelevant IgG
Regardless of treatment with aT or isotype-matched
irrelevant IgG, the mean body weight of nephritic rats
treated with repeated ATS injections was significantly less
than that of non-nephritic animals at 4 and 8 weeks of the
experimental period (Table 1). However, treatment with
aT did not significantly change the weight of nephritic or
non-nephritic rats.
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Fig. 1. Renal cortical expression of (A) TGF-b1, (B) TGF-b2, and (C)
TGF-b3 mRNA at 8 weeks in nephritic and non-nephritic rats treated
with aT or irrelevant IgG. Expression of TGF-b1 and TGF-b2 mRNA,
but not TGF-b3 mRNA, in the renal cortex of nephritic rats treated
with irrelevant IgG was significantly higher than that of IgG-treated
non-nephritic rats at 8 weeks. Twice weekly administration of aT
for 4 weeks, from days 7 to 35, significantly suppressed the elevated
expression of TGF-b1 and TGF-b2 mRNA in nephritic kidneys.
Neither marked increases of TGF-b1, TGF-b2, and TGF-b3 mRNA
expression, nor effects of aT treatment on their expression were noted
in non-nephritic kidneys. Data analysis was performed using Light
Cycler software. To quantify the gene copy number of the target cDNA
that was reverse transcribed from RNA in the samples, 1:10 serially-
diluted PCR products of the target cDNA, which had been generated
Renal cortical TGF-b expression
Expression levels of TGF-b1 and TGF-b2 mRNAs in
the renal cortex of IgG-treated nephritic rats were signifi-
cantly higher than those of IgG-treated non-nephritic rats
at 4 (data not shown) and 8 weeks (2.3-fold and 2.7-fold
increases in TGF-b1 and TGF-b2 mRNA, respectively)
(Fig. 1). Twice weekly administration of aT for 4 weeks,
from days 7 to 35, significantly suppressed the elevated
expression of these TGF-b isoforms in nephritic kidneys
at 4 (data not shown) and 8 weeks (Fig. 1). On the other
hand, the levels of TGF-b3 mRNA expression were not
significantly different among the groups.
aT treatment reduced proteinuria and prevented
renal insufficiency
As shown in Figure 2A, proteinuria progressively wors-
ened in rats treated with repeated ATS injections, while
administration of aT from days 7 to 35 resulted in signif-
icant improvement of proteinuria on and after 4 weeks.
No significant proteinuria was observed in non-nephritic
rats, regardless of treatment with aT or irrelevant IgG
throughout the experimental period of 8 weeks.
At baseline, the concentration of blood urea nitrogen
was identical in each group (data not shown). Significant
increases in blood urea nitrogen levels were noted in IgG-
treated nephritic rats compared with IgG-treated non-
nephritic rats at 8 weeks (35.5 ± 2.0 vs. 18.4 ± 1.0 mg/dL,
respectively; P < 0.05). Four-week treatment with aT sig-
nificantly prevented the increase in blood urea nitrogen
in nephritic rats at 8 weeks (Fig. 2B).
Histopathologic changes. Consistent with our previ-
ous reports [13, 14], two ATS injections, given 1 week
apart, induced chronic progressive glomerulonephritis
with tubulointerstitial lesions in rats (Fig. 3C). In addition
to proliferation of mesangial cells with increased matrix
accumulation, periglomerular and focal tubulointerstitial
lesions included increases in ECM deposition, mononu-
clear cell infiltration, and tubular atrophy at 8 weeks.
Rats with chronic progressive ATS nephritis treated
twice weekly with aT from days 7 to 35 showed marked
amelioration of these glomerular and tubulointerstitial
changes at 8 weeks (Fig. 3C vs. 3D). No notable glomeru-
lar or tubulointerstitial lesions were observed in non-
nephritic animals treated with either aT or irrelevant
IgG (Fig. 3A and 3B). Both activity and chronicity in-
dexes were significantly higher in nephritic rats treated
with irrelevant IgG compared with non-nephritic rats. aT
beforehand using the same primers, were included in each run and the
standard curves were obtained. The ratios of TGF-b1, TGF-b2, and
TGF-b3 mRNA to GAPDH mRNA were calculated in each sample.
∗P < 0.01 vs. non-nephritic groups; #P < 0.05 vs. nephritic rats treated
with irrelevant IgG. Values are mean ± SEM calculated from the data
of 7 rats in each group.
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Fig. 2. Levels of urinary protein excretion and blood urea nitrogen at
8 weeks. (A) Levels of proteinuria increased progressively in rats re-
ceiving repeated ATS injections (closed circles) and administration of
aT from days 7 to 35 (closed triangles) resulted in significant decreases
in levels of proteinuria on and after 4 weeks. No significant protein-
uria was observed in non-nephritic rats regardless of treatment with
aT (open triangles) or irrelevant IgG (open circles) throughout the ex-
perimental period of 8 weeks. (B) Blood urea nitrogen was measured
at 8 weeks after the first injection of ATS. Blood urea nitrogen levels
of nephritic rats treated with IgG were significantly higher than those
of non-nephritic rats. Treatment with aT significantly reduced blood
urea nitrogen levels in nephritic rats, although no remarkable changes
were noted in non-nephritic animals. ∗P < 0.05 vs. non-nephritic groups;
#P < 0.05 vs. nephritic rats treated with irrelevant IgG. Values are mean
± SEM calculated from the data of 7 rats in each group.
treatment resulted in significant amelioration of both of
these indexes in nephritic rats (Fig. 3E).
Renal cortical OH-proline levels and expression of
COL1A2 and PAI-1. Renal accumulation of OH-
proline–containing proteins such as collagens is a fea-
ture of increased ECM deposition in nephritis associated
with glomerulosclerosis and tubulointerstitial fibrosis. In
addition, PAI-1 is known to be induced by the action of
TGF-b and is a potent inhibitor of plasminogen activator
that takes part in matrix degradation [21, 22]. To evalu-
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Fig. 3. Light microscopic images of kidneys at 8 weeks in (A) non-
nephritic rats treated with irrelevant IgG, (B) non-nephritic rats treated
with aT, (C) nephritic rats treated with irrelevant IgG, and (D) nephritic
rats treated with aT, and (E) semi-quantitative histopathologic evalu-
ation of renal lesions. Marked mesangial matrix expansion, interstitial
fibrosis, tubular atrophy, and interstitial mononuclear infiltration were
noted in the renal cortex of nephritic rats treated with irrelevant IgG
(C). In nephritic rats treated with aT, these glomerular and tubuloint-
erstitial lesions were markedly ameliorated at 8 weeks (D). No remark-
able renal changes were noted in non-nephritic rats treated with IgG
or aT (A and B, respectively). (Periodic acid-Schiff stain, magnifica-
tions ×200) (E) Both activity and chronicity indexes were significantly
increased in nephritic rats treated with irrelevant IgG compared to non-
nephritic rats. aT treatment significantly ameliorated both indexes in
nephritic rats. ∗P < 0.05 vs. non-nephritic rats; # P < 0.05 vs. nephritic
rats treated with irrelevant IgG. Values are mean ± SEM calculated
from the data of 7 rats in each group.
ate the effect of aT on ECM deposition in chronic pro-
gressive ATS nephritis, we investigated the renal cortical
OH-proline levels and expression of COL1A2 and PAI-1.
In non-nephritic rats, the renal OH-proline concentra-
tion at 8 weeks was not significantly different between
rats treated with aT and those treated with irrelevant IgG
(Fig. 4A). In contrast, the renal OH-proline concentra-
tion was markedly increased in nephritic rats treated with
IgG at 8 weeks (P < 0.01 vs. IgG-treated non-nephritic
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Fig. 4. Levels of (A) hydroxyproline (OH-proline), (B) immunofluo-
rescence images of type I collagen, and (C) levels of COL1A2 mRNA
measured by real-time RT-PCR in renal cortical tissues of nephritic and
non-nephritic rats at 8 weeks. (A) Levels of OH-proline were signifi-
cantly increased in the renal cortex of chronic progressive nephritic rats
induced by repeated ATS injections, and aT treatment significantly de-
creased the levels in nephritic rats. (B) Type I collagen protein was noted
scarcely in glomeruli and moderately in interstitium of non-nephritic
rats treated with aT or IgG. In IgG-treated nephritic rats, increased
deposition of type I collagen was noted in the glomerular and tubu-
lointerstitial lesions compared with those of IgG-treated non-nephritic
animals, and treatment with aT markedly suppressed its glomerular and
tubulointerstitial deposition. (C) COL1A2 mRNA was significantly in-
creased in IgG-treated nephritic rats compared with non-nephritic ani-
mals. Four-week treatment with aT prevented the increase of COL1A2
mRNA expression at 8 weeks, while aT treatment did not significantly
change its expression in non-nephritic kidneys. Data analysis was per-
formed using Light Cycler software. To quantify the gene copy number
of the target cDNA that was reverse transcribed from RNA in the sam-
ples, 1:10 serially-diluted PCR products of the target cDNA, that had
been generated beforehand using the same primers, were included in
each run and the standard curves were obtained. The ratios of COL1A2
mRNA to GAPDH mRNA were calculated in each sample. ∗P < 0.01
vs. non-nephritic rats; ∗∗P < 0.05 vs. non-nephritic rats; #P < 0.05 vs.
nephritic rats treated with irrelevant IgG. Values are mean ± SEM cal-
culated from the data of 7 rats in each group.
rats). aT treatment significantly decreased the levels in
nephritic rats (P < 0.05 vs. IgG-treated nephritic rats).
Immunofluorescence analysis showed that type I col-
lagen protein was scarce in glomeruli and moderate in
interstitium in non-nephritic rats treated with aT or IgG
(Fig. 4B). In IgG-treated nephritic rats, increased de-
position of type I collagen was noted in the glomeru-
lar and tubulointerstitial lesions compared with those
in IgG-treated non-nephritic animals, and treatment
with aT markedly suppressed its deposition in the
glomeruli and tubulointerstitium. To confirm this phe-
nomenon, we also examined COL1A2 mRNA expres-
sion in renal cortical tissues. As shown in Figure 4C,
COL1A2 mRNA was significantly increased in IgG-
treated nephritic rat kidneys compared with non-
nephritic ones (P < 0.05). Four-week treatment with
aT prevented the increase of COL1A2 mRNA ex-
pression at 8 weeks, indicating that aT treatment in-
hibited the enhanced COL1A2 production in chronic
progressive ATS nephritic kidneys.
Both PAI-1 protein and mRNA expression were
markedly increased in IgG-treated nephritic rat kidneys,
and aT treatment almost completely prevented the ex-
pression at 8 weeks (Fig. 5). These results suggested that
aT treatment efficiently suppressed renal accumulation
of ECM in chronic progressive ATS nephritis.
Cortical expression of TGF-b/Smad signaling compo-
nents. Recent studies have demonstrated that Smad
proteins are important intracellular transducers of TGF-
b signaling, and that activated TGF-b receptors induce
phosphorylation of Smad2 and Smad3, which translo-
cate into the nucleus and bind to their target genes [23].
Therefore, we next examined the TGF-b/Smad signaling
pathway to elucidate the molecular mechanisms of reno-
protective effects of aT.
No differences in the cortical levels of TbRII and
Smad2 proteins were noted between non-nephritic rats
treated with IgG and those treated with aT at 8 weeks
(Fig. 6A and C). The levels of TbRII and Smad2 pro-
teins were increased in the renal cortical tissues of IgG-
treated nephritic rats; however, aT treatment markedly
decreased their levels. In contrast, no remarkable differ-
ences in the renal cortical levels of Smad3 and Smad4
proteins were observed among nephritic and non-
nephritic rats treated with either aT or IgG (Fig. 6A
and C).
To elucidate the signaling activity of R-Smads, we then
investigated the levels of phosphorylated Smad2 and
Smad3 in the nuclear protein fractions prepared from
renal cortical tissues (Fig. 6B and C). There were no dif-
ferences in the levels of nuclear phosphorylated Smad2
and Smad3 in non-nephritic rats regardless of treatment
with aT or IgG at 8 weeks. In contrast, both nuclear phos-
phorylated Smad2 and Smad3 were increased markedly
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Fig. 5. Western blotting of (A) PAI-1 protein and levels of PAI-1 (B)
mRNA measured by real-time RT-PCR in renal cortical tissues of
nephritic and non-nephritic rats at 8 weeks. Both (A) PAI-1 protein
and (B) mRNA expression were markedly increased in IgG-treated
nephritic rat kidneys at 8 weeks and aT treatment almost completely
prevented the expression. Data analysis was performed using Light Cy-
cler software. To quantify the gene copy number of the target cDNA
that was reverse transcribed from RNA in the samples, 1:10 serially-
diluted PCR products of the target cDNA, that had been generated
beforehand using the same primers, were included in each run and the
standard curves were obtained. The ratios of PAI-1 mRNA to GAPDH
mRNA were calculated in each sample. ∗P < 0.05 vs. non-nephritic rats;
#P < 0.05 vs. nephritic rats treated with irrelevant IgG. Values are mean
± SEM calculated from the data of 7 rats in each group.
in the renal cortical tissues of IgG-treated nephritic rats
compared with those in non-nephritic animals, indicat-
ing the enhanced TGF-b/Smad signaling in the nephritic
kidneys. In addition, the levels of nuclear phosphorylated
Smad3 were more abundant than those of phosphory-
lated Smad2 in the cortices of nephritic and non-nephritic
kidneys. Moreover, treatment with aT markedly sup-
pressed the nuclear accumulation of phosphorylated
Smad2 and Smad3 in nephritic kidneys to levels almost
identical to those in non-nephritic kidneys. These bio-
chemical data were also confirmed by the immunohis-
tochemical study as shown in Figure 7. Phosphorylated
Smad2 and Smad3 in IgG-treated nephritic rat kidneys
were preferentially localized in the nuclei of glomerular
and tubular cells when compared with non-nephritic rat
kidneys (Fig. 7A vs. C and 7E vs. G). Furthermore, double
immunostaining for TbRII and phosphorylated Smad2/3
in nephritic kidney specimens at 8 weeks demonstrated
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whole (A) cellular and (B) nuclear extracts obtained from renal corti-
cal tissues of nephritic and non-nephritic rats at 8 weeks, and their (C)
densitometric intensity. (A) Levels of TGF-b type II receptor (TbRII)
and Smad2 were increased in the renal cortical tissues of nephritic rats
treated with IgG compared with those of non-nephritic rats, whereas
no significant changes were observed in the levels of Smad3 and Smad4.
Treatment with aT reduced the levels of TbRII and Smad2 in nephritic
rats. (B) No remarkable differences in the levels of nuclear phospho-
rylated Smad2 (P-Smad2) and Smad3 (P-Smad3) were noted in non-
nephritic rats regardless of treatment with aT or IgG at 8 weeks. In
contrast, both nuclear P-Smad2 and P-Smad3 were markedly increased
in the renal cortical tissues of IgG-treated nephritic rats compared with
levels in non-nephritic animals. Treatment with aT markedly suppressed
the nuclear accumulation of P-Smad2 and P-Smad3 in the nephritic kid-
neys. In addition, nuclear P-Smad3 was more abundant than P-Smad2
in the cortices of nephritic and non-nephritic rat kidneys. (C) Symbols
are: ( ) non-nephritic rats treated with irrelevant IgG; ( ) non-nephritic
rats treated with aT; () nephritic rats treated with irrelevant IgG; ( )
nephritic rats treated with aT.
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shown in (K) and (L), respectively. Note the weak nuclear staining of P-Smad2/3 in a few glomerular and distal tubular cells of IgG-treated (arrows in
A and E, respectively) and aT-treated (arrows in B and F, respectively) non-nephritic rat kidneys. Increased nuclear immunoreactivity for P-Smad2/3
was noted in the glomerular endothelial, epithelial, mesangial, Bowman’s capsular epithelial, tubular cells, and interstitial infiltrating mononuclear
cells of IgG-treated nephritic rat kidneys (arrows in C and G). Treatment with aT markedly decreased the number of P-Smad2/3-positive nuclei in
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nuclei in the glomerular and tubular cells are shown in panels K and L, respectively. ∗P < 0.05 vs. non-nephritic groups; #P < 0.05 vs. nephritic rats
treated with irrelevant IgG. Values are mean ± SEM calculated from the data of 7 rats in each group.
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Fig. 8. Electrophoretic mobility shift assay
(EMSA) of Smad3-Smad binding element
(SBE) complex in nuclear extracts from renal
cortical tissues of non-nephritic and nephritic
rats at 8 weeks. EMSA was performed using
32P-labeled Smad-binding element (SBE) of
the PAI-1 promoter as a probe. The specific
shifted bands were observed in nuclear ex-
tracts (NE) from renal cortical tissue of non-
nephritic and nephritic rats (A, lanes 2 and
3). The shifted band was considered to com-
prise Smad3-SBE complexes, because it was
super-shifted by incubation with anti-Smad3
antibody (aSmad3) (A, lanes 4 and 5) but not
with control IgG (IgG) (A, lanes 6 and 7),
and was diminished by incubation with excess
amounts of cold wild-type probes (WT, ×50)
(A, lanes 8 and 9) but not with excess amounts
of cold mutant probes (MT, ×50) (A, lanes
10 and 11). Levels of Smad3-SBE complex
were increased in nuclear extracts from IgG-
treated nephritic rat kidneys compared with
those from non-nephritic rat kidneys (A, lanes
2 vs. 3, and B, lanes 2 vs. 3). Treatment with aT
resulted in significant decreases of binding ac-
tivity for the SBE (B, lanes 3 vs. 4). Represen-
tative data of three independent experiments
are shown.
that increased nuclear accumulation of phosphorylated
Smad 2/3 was noted in glomerular, tubular, and intersti-
tial infiltrating mononuclear cells with increased TbRII
expression (Fig. 7I and J). aT-treated nephritic kidneys
showed decreased nuclear localization of phosphorylated
Smad2/3 in the glomeruli and tubulointerstitium com-
pared with those in IgG-treated nephritic kidneys (Fig. 7C
vs. D and 7G vs. H). These data indicated that aT treat-
ment suppressed not only the quantities but also the ac-
cumulation of phosphorylated Smad2 and Smad3 in the
renal cortical cell nuclei in rats with chronic progressive
ATS nephritis.
Activation of Smad3 binding to Smad-binding element
(SBE). Following activation by TbR in response to
TGF-b stimuli, activated Smad3 couples with Smad4,
translocates into the nucleus, and binds to certain DNA
sites such as SBE for the Smad3/4 complex in the target
gene promoters [24]. Finally, we examined whether nu-
clear protein binding to SBE is enhanced in nephritic rat
kidneys using EMSA.
32P-labeled SBE probe of the PAI-1 promoter was
clearly shifted by the addition of nuclear extracts ob-
tained from non-nephritic and nephritic rat cortical tis-
sues (Fig. 8A, lanes 1 vs. 2 and 1 vs. 3, respectively).
However, the binding level was markedly increased in nu-
clear extracts obtained from nephritic rat kidneys (lane
3) compared with non-nephritic kidneys (lane 2). The
band was further shifted following incubation with anti-
Smad3 antibody (lanes 2 vs. 4 in non-nephritic kidneys
and lanes 3 vs. 5 in nephritic kidneys), whereas incuba-
tion with control IgG did not affect the band (lanes 2 vs. 6
in non-nephritic kidneys and lanes 3 vs. 7 in nephritic kid-
neys). Incubation with anti-Smad2 antibody caused a triv-
ial change of the band (data not shown). The shifted band
disappeared in the presence of excess amounts of cold
wild-type SBE (lanes 8 and 9) but not mutant SBE (lanes
10 and 11). This suggested that the shifted band mostly
consisted of Smad3-SBE complexes and that the bind-
ing of Smad3 to SBE was markedly increased in chronic
progressive ATS nephritic kidneys.
Using this EMSA assay, we evaluated the effects of
4-week aT treatment on Smad3-SBE complex forma-
tion in the nephritic kidneys at 8 weeks. We found that
aT treatment significantly decreased the formation of
Smad3-SBE complex in the nephritic kidneys (Fig. 8B,
lanes 3 vs. 4). Taken together, these data strongly sug-
gested that the activated TGF-b/Smad signaling pathway
plays a pathogenic role in the development of proteinuria,
renal insufficiency, and intrarenal ECM accumulation in
chronic progressive ATS nephritis. We also demonstrated
that blockade of TGF-b/Smad signaling pathway by
4-week aT treatment markedly reduced these functional
and morphologic derangement involved in chronic pro-
gressive ATS nephritis at 8 weeks.
DISCUSSION
In the present study, we evaluated the effects of neu-
tralizing aT, administered twice weekly for 4 weeks
from days 7 to 35, on renal insufficiency and fibrosis,
and attempted to define the intrarenal TGF-b /Smad
signaling system involved in chronic progressive ATS
nephritis induced by repeated ATS injections. Our re-
sults demonstrated that 4-week administration of aT,
which neutralizes the activity of all three mammalian
isoforms of TGF-b , TGF-b1, -b2, and -b3, ameliorated
proteinuria, renal dysfunction, and pathologic glomeru-
lar and tubulointerstitial ECM deposition at 8 weeks in
chronic progressive ATS nephritis. aT treatment signifi-
cantly suppressed the elevated expression of TGF-b1 and
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-b2 in nephritic kidneys at 4 as well as 8 weeks. Interrup-
tion of TGF-b autoinduction [25, 26] by aT treatment
may be involved in the suppression of TGF-b1 and -b2
mRNA expression in the nephritic kidneys of rats treated
with aT. On the other hand, there were no differences
in TGF-b3 mRNA expression levels among the groups.
Although the reason for the different TGF-b3 mRNA
expression relative to that of TGF-b1 and -b2 mRNAs in
chronic progressive ATS nephritic kidneys is not clearly
understood, a distinct role for TGF-b3 in the progres-
sion of fibrosis compared with TGF-b1 and b2 has been
reported [27].
Not only decreases of ECM production as evidenced
by the decreases of renal cortical OH-proline content,
type I collagen deposition and COL1A2 mRNA expres-
sion, but also increased ECM degradation attributable to
decreased PAI-1 expression could be involved in the anti-
fibrotic effects of aT. In addition to direct inhibition of
TGF-b , which was expressed in the glomerular and tubu-
lointerstitial lesions in chronic progressive ATS nephri-
tis, the associated decrease in proteinuria might have also
participated in amelioration of fibrotic tubulointerstitial
lesions in aT-treated nephritic rats [28].
Although the ameliorative effects of long-term admin-
istration of aT were reported in db/db diabetic mouse
nephropathy [6] and mouse cyclosporin A nephropathy
[9], aT was administered until the end point of the exper-
imental period (8 weeks) in these studies. In our study,
however, aT was administered twice weekly only from
days 7 to 35 and the ameliorative effects were noted 3
weeks after the cessation of its administration. These data
indicate that the initial 4-week suppression of pathogenic
TGF-b activity by aT is therapeutically potent in prevent-
ing the development of chronic ATS nephritis, which itself
has a progressive potential.
Recently, Smad proteins have been identified as pre-
dominant components in the TGF-b signaling pathway
[3, 24]. TGF-b signals through the heteromeric complex
of TbRI and TbRII, transmembrane serine/threonine ki-
nase receptors. Activation of the receptor complex occurs
when type II receptor kinase transphosphorylates the GS
domain of type I kinase. The activated type I kinase as-
sociates transiently with, and also phosphorylates such
R-Smads as Smad2 and Smad3. Once phosphorylated, R-
Smads dissociate from the receptor, bind to Smad4, and
then enter the nucleus. We have previously shown that
TGF-b1 and TbRs were up-regulated in chronic progres-
sive ATS nephritis [13, 14]. However, the role of Smad
signaling components involved in the model has not been
identified.
To investigate the Smad signaling involved in chronic
progressive ATS nephritis, we first examined the whole
cellular as well as nuclear expression and localization of
TGF-b/Smad signaling components in the renal cortical
tissues of both nephritic and non-nephritic rats. In agree-
ment with previous reports [29, 30], TbRII and Smad2
proteins were increased in the renal cortical cells of rats
with chronic progressive ATS nephritis compared with
those in non-nephritic animals, while no significant differ-
ences in the cortical cellular levels of Smad3 and Smad4
proteins were noted between nephritic and non-nephritic
rat kidneys. On the other hand, the nuclear localization
of phosphorylated Smads 2 and 3 was markedly increased
in nephritic compared with non-nephritic rat kidneys. Al-
though Ostendorf et al [30] recently reported that phos-
phorylated Smad2 staining predominantly localized to
nuclei in the glomerular endothelial cells in acute re-
versible anti-Thy-1.1 nephritis, nuclear accumulation of
phosphorylated Smads 2 and 3 was noted in glomeru-
lar endothelial, epithelial, mesangial, Bowman’s capsular
epithelial, tubular, and interstitial infiltrating mononu-
clear cells in chronic ATS nephritis with tubulointersti-
tial lesions in the present study. This discrepancy may
be attributable to the fact that the antibody used in our
study reacts with both phosphorylated Smads 2 and 3,
and also to the difference in kidney cells with accelerated
TGF-b/Smad signaling between acute reversible anti-
Thy-1.1 nephritis and chronic progressive ATS nephritis
with tubulointerstitial lesions.
Smad3 and Smad4 can bind to the specific nucleotide
sequence CAGA box, called the consensus SBE. A num-
ber of such Smad3/Smad4 binding elements have been
characterized in the promoters of some TGF-b1 respon-
sive genes. These include genes encoding PAI-1, types I
and IV collagens, Smad7, c-jun, and junB [19, 21, 31, 32].
Using EMSA for the SBE in the PAI-1 promoter that
binds specifically to the Smad3/Smad4 complex [19], we
also demonstrated that the SBE binding activity of Smad3
in nuclear proteins extracted from the renal cortical tis-
sues of rats with chronic progressive ATS nephritis were
markedly increased. Moreover, Smad3 binding activity
to SBE was markedly suppressed in nephritic rat kid-
neys treated with aT compared with that in IgG-treated
nephritic kidneys. To the best of our knowledge, these
observations are the first to prove that the specific down-
stream TGF-b signaling to the PAI-1 promoter mediated
by Smad3 is activated in kidneys with chronic progressive
glomerulonephritis and could be suppressed effectively
by aT treatment. Considering these findings together
with the increased nuclear localization of phosphorylated
R-Smads, Smad2 and Smad3, in nephritic rat kidneys, it is
plausible to consider that overactivation of TGF-b/Smad
signaling plays a pathogenic role in the functional and
structural derangement that develops in chronic progres-
sive ATS nephritis. However, in the present study, we
could not determine whether the binding of Smad2 to
its specific target genes was activated similarly in the
nephritic kidneys, because, in contrast to Smad3, Smad2
does not bind to DNA directly [33]. Further studies are
needed to investigate whether Smad2 and Smad3 each
has a different subset of target genes and thus regulates
distinct gene expressions in the nephritic kidneys.
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CONCLUSION
Our study demonstrated the following: (1) the expres-
sion of type I collagen, PAI-1, and TGF-b /Smad sig-
naling components including TGF-b1, TGF-b2, TbRII,
and Smad2; (2) nuclear localization of phosphorylated
Smad2 and Smad3; and (3) binding of Smad3 to SBE
in PAI-1 promoter, were increased in the renal corti-
cal tissues of rats with chronic progressive ATS nephri-
tis associated with progressive glomerulosclerosis and
tubulointerstitial fibrosis; and (4) four-week aT treat-
ment caused amelioration of chronic progressive ATS
nephritis at 8 weeks, which was associated with decreases
of intrarenal TGF-b/Smad signaling activity. These data
suggest that strategies to down-regulate TGF-b/Smad
signaling could provide a valuable adjunctive therapy
in patients with chronic progressive glomerulonephritis
who are destined for end-stage renal failure.
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